A controlled effects approach to assessing immune correlates of protection
Biostatistics · 18.10.2023 · 24 (4) · 850-865
DOI: 10.1093/biostatistics/kxac024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biostatistics, online erschienen am 15.07.2022. Verfasst von Peter B Gilbert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA and Department of Biostatistics, University of Washington, S…. Hauptthemen laut MEDLINE: Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
An immune correlate of risk (CoR) is an immunologic biomarker in vaccine recipients associated with an infectious disease clinical endpoint. An immune correlate of protection (CoP) is a CoR that can be used to reliably predict vaccine efficacy (VE) against the clinical endpoint and hence is accepted as a surrogate endpoint that can be used for accelerated approval or guide use of vaccines. In randomized, placebo-controlled trials, CoR analysis is limited by not assessing a causal vaccine effect. To address this limitation, we construct the controlled risk curve of a biomarker, which provides the causal risk of an endpoint if all participants are assigned vaccine and the biomarker is set to different levels. Furthermore, we propose a causal CoP analysis based on controlled effects, where for the important special case that the biomarker is constant in the placebo arm, we study the controlled vaccine efficacy curve that contrasts the controlled risk curve with placebo arm risk. We provide identification conditions and formulae that account for right censoring of the clinical endpoint and two-phase sampling of the biomarker, and consider G-computation estimation and inference under a semiparametric model such as the Cox model. We add modular approaches to sensitivity analysis that quantify robustness of CoP evidence to unmeasured confounding. We provide an application to two phase 3 trials of a dengue vaccine indicating that controlled risk of dengue strongly varies with 50$\%$ neutralizing antibody titer. Our work introduces controlled effects causal mediation analysis to immune CoP evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA and Department of Biostatistics, University of Washington, Seattle, WA, USA.
- Department of Biostatistics, University of Washington, Seattle, WA, USA.
- Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, 1100 Fairview Ave N, PO Box 19024 Seattle, WA 98109, USA and University of Washington, Department of Biostatistics, Hans Rosling Center for Populat…
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Gilbert, P. B., Fong, Y., Kenny, A., & Carone, M. (2023). A controlled effects approach to assessing immune correlates of protection. Biostatistics, 24(4), 850-865. https://doi.org/10.1093/biostatistics/kxac024
Vancouver
Gilbert PB, Fong Y, Kenny A, Carone M. A controlled effects approach to assessing immune correlates of protection. Biostatistics. 2023;24(4):850-865. doi:10.1093/biostatistics/kxac024
BibTeX
@article{Gilbert2023,
author = {Gilbert, Peter B and Fong, Youyi and Kenny, Avi and Carone, Marco},
title = {A controlled effects approach to assessing immune correlates of protection},
journal = {Biostatistics},
year = {2023},
volume = {24},
number = {4},
pages = {850--865},
doi = {10.1093/biostatistics/kxac024}
}
EUVIMED